The Guidelines for the
Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents were
updated March 23 and are available at the AIDS info web site.

The guidelines were developed
and updated by the panel on Clinical Practices for Treatment of HIV Infection,
convened by the Department of Health and Human Services.

The changes in this update
are outlined here:

1.
"Table 12a — Antiretroviral Regimens Recommended for Treatment of HIV-1 Infection
in Antiretroviral Naive Patients": Additions: 01 Fosamprenavir and ritonavir-boosted
fosamprenavir to be added as part of Alternative PI-based regimens for initiation
of therapy in treatment-naive patients. "Abacavir + lamivudine" has been added
as an alternative 2-NRTI backbone.

Deletions: Ritonavir-boosted
amprenavir has been removed as an alternative PI-based regimen for initiation
of therapy in treatment naive patients. Indinavir (unboosted) has been removed
as an alternative PI-based regimen for initiation of therapy in treatment-naive
patients.

2. New safety information
regarding the risks of nevirapine-associated symptomatic hepatic events has
been added to the text of the guidelines (sections on "NNRTI-Based Regimens"
and "Hepatotoxicity") and the respective tables (Tables 12a, 12b, and 19).